caa a22 4500 469118687 CHVBK 20180323133132.0 cr unu---uuuuu 170328e19921201xx s 000 0 eng 10.1007/BF02247726 doi (NATIONALLICENCE)springer-10.1007/BF02247726 Amperozide and clozapine but not haloperidol or raclopride increase the secretion of oxytocin in rats [Elektronische Daten] [Kerstin Uvnäs-Moberg, Pawel Alster, Torgny Svensson] The aim of the present study was to investigate whether amperozide, an antipsychotic drug which possesses anti-aggressive and anxiolytic-like properties, stimulates the secretion of oxytocin and if so, by which receptor mechanism. For this purpose, female or male Sprague Dawley rats were given amperozide (0.5, 2.5 and 5.0 mg/kg IP), ritanserin (5.0 mg/kg), raclopride (2.0 mg/kg) and prazosin (1.0 mg/kg) and were subsequently decapitated for collection of blood (30 and 120 min) after injection. Oxytocin levels were measured with radioimmunoassay. Amperozide 2.5 and 5 mg/kg increased plasma levels of oxytocin significantly (P<0.05 and <0.001). The effect appeared maximal about 30 min after injection of the drug and oxytocin levels were almost back to basal within 120 min. Similar effects were obtained in female and male rats as well as in animals that were freely fed or food deprived for 24 h. CSF levels of oxytocin were also increased. Ritanserin, a 5-HT2-receptor antagonist but not the D2 receptor antagonist raclopride or the α1-adrenoceptor antagonist prazosin stimulated oxytocin release. In addition, clozapine, a neuroleptic with potent HT2-antagonistic properties, was a potent releaser of oxytocin, whereas haloperidol was without effect. A possible role for oxytocin in the behavioural effects of amperozide and clozapine remains to be explored. Springer-Verlag, 1992 Amperozide nationallicence Clozapine nationallicence Oxytocin levels nationallicence 5-HT2-receptors nationallicence Uvnäs-Moberg Kerstin Department of Pharmacology, Karolinska Institute, P.O. Box 60400, S-10401, Stockholm, Sweden aut Alster Pawel Department of Pharmacology, Karolinska Institute, P.O. Box 60400, S-10401, Stockholm, Sweden aut Svensson Torgny Department of Pharmacology, Karolinska Institute, P.O. Box 60400, S-10401, Stockholm, Sweden aut Psychopharmacology Springer-Verlag 109/4(1992-12-01), 473-476 0033-3158 109:4<473 1992 109 213 https://doi.org/10.1007/BF02247726 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02247726 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Uvnäs-Moberg Kerstin Department of Pharmacology, Karolinska Institute, P.O. Box 60400, S-10401, Stockholm, Sweden aut NATIONALLICENCE 700 1- Alster Pawel Department of Pharmacology, Karolinska Institute, P.O. Box 60400, S-10401, Stockholm, Sweden aut NATIONALLICENCE 700 1- Svensson Torgny Department of Pharmacology, Karolinska Institute, P.O. Box 60400, S-10401, Stockholm, Sweden aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 109/4(1992-12-01), 473-476 0033-3158 109:4<473 1992 109 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer